China's biopharmaceutical market will reach 478.5 billion yuan, and overseas returnees will be the key to innovation

[market analysis of China Pharmaceutical network] biomedical industry is regarded as a sunrise industry in China, which has developed rapidly in recent years According to the public data, the market scale of China's biomedical industry in 2017 is 218.5 billion yuan, and it is expected that in 2018, the market scale of China's biomedical industry will exceed 250 billion yuan; by 2022, it will grow to 478.5 billion yuan According to the industry, there will be high-value Unicorn companies in the future, and independent innovation will become the key to the development of biomedical enterprises According to the industry, independent innovation is reflected in many aspects, such as technology innovation, R & D innovation, enterprise management system innovation and talent innovation Especially in terms of talents, there is a lack of innovative talents in the field of biomedicine in China, so it is very important to strengthen the introduction of talents The author understands that in recent years, all parts of China have issued "high-profile" talent introduction policies, planted sycamore trees to attract Phoenix, and opened the "key" for transformation and development of all parts For example, Ningxia has implemented the "domestic talent introduction 312 plan", which has arranged a special fund of 3 million yuan every year since 2012, mainly to help the introduced high-level talents improve their working and living conditions Guangdong Zhuhai issued the "talent recruitment order" In the next five years, Zhuhai will invest more than 2.5 billion yuan every year to attract all kinds of talents Focusing on the strategic emerging industries and future industries that Zhuhai focuses on, Zhuhai will increase the innovation and entrepreneurship team from 20 million yuan to 100 million yuan, and give high-level talent entrepreneurship projects 2 million yuan In 2017, Hefei launched "20 new policies for talents", and on April 26 this year, it issued "several policies on further supporting talents to enrich innovation and entrepreneurship" It is reported that in the next seven years, Hefei will provide more than 10 billion yuan of funds to "support people" For the urgently needed talents, it will issue 2000 yuan to 3000 yuan of living subsidies each month within three years according to the types of talents, which will cover all kinds of talents such as college graduates, returned overseas students and professional and technical talents, and provide support in settling down and purchasing houses In addition to material rewards, many places also play the "emotional card" to attract talents For example, the "three lead and three return" in Shenyang will lead the villagers back to their hometown, the alumni back to Shenyang and the comrades in arms back to their residence Attract talents with environment and retain talents with emotion These policies have also attracted a large number of overseas talents in the field of biomedicine to return home to start their own businesses The phenomenon of "return fever" has brought new vitality and impetus to the development of domestic biomedicine At the same time, with the continuous promotion of the reform of drug review and approval system and the change of people's health concept, the biomedical industry ushered in a golden development period, providing a good development space for returnees As we all know, the biomedical industry has the characteristics of high technology content, long development cycle, high risk and large investment Although returnees have relatively mature experience and advanced concept, they can not avoid the bottleneck of technology and capital In this regard, industry experts suggest that China should consider providing more support according to the characteristics of biomedical industry, such as increasing the practicality of intellectual property value transformation, so that more researchers can realize the transformation and industrialization of research results "Scientists need more money to support research, and support at the national level is essential." The industry believes that only with support from many aspects can returnees focus on technology research and development, and enable scientific research and innovation, so as to help China's biopharmaceutical industry develop better and more stably.